News: Basilea

News

News Subscription

Apr 19. 2018

Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting of Shareholders

Read more

Apr 18. 2018

Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole

Read more

Apr 17. 2018

Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

Read more

Apr 09. 2018

Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma

Read more

Mar 06. 2018

Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana

Read more

Mar 01. 2018

Basilea names Adesh Kaul as new member of its Management Committee

Read more

Feb 27. 2018

Basilea reports significantly improved financial results in 2017

Read more

Feb 23. 2018

Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract

Read more

Feb 21. 2018

Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors

Read more

Jan 10. 2018

Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific

Read more

previous
1
…
19
20
21
…
32
next